Accessibility helpSkip to navigationSkip to contentSkip to footer

Cookies on FT Sites

We use cookies and other data for a number of reasons, such as keeping FT Sites reliable and secure, personalising content and ads, providing social media features and to analyse how our Sites are used.

Accept cookies
Manage cookies
  • Sign In
  • Subscribe
Open side navigation menuOpen search bar
Financial Times
SubscribeSign InmyFT
  • Home
  • World
    Sections
    • World Home
    • Global Economy
    • UK
    • US
    • China
    • Africa
    • Asia Pacific
    • Emerging Markets
    • Europe
    • War in Ukraine
    • Americas
    • Middle East & North Africa
    • Australia & NZ
    Most Read
    • Israel plunges into political turmoil over Benjamin Netanyahu’s judicial reforms
    • Israel protests intensify after Netanyahu sacks defence minister
    • China’s economic rebound weaker than expected, warns Maersk
    • Italy seizes Banksy-funded rescue ship as migrant crossings surge
    • Vladimir Putin plans to deploy tactical nuclear weapons in Belarus
  • US
    Sections
    • US Home
    • US Economy
    • US Companies
    • US Politics & Policy
    Most Read
    • Companies
      Sections
      • Companies Home
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
      Most Read
      • European ammunition maker says plant expansion hit by energy-guzzling TikTok site
      • First Citizens to buy failed Silicon Valley Bank
      • Saudi National Bank chair resigns following Credit Suisse comments
      • Air India boss hails biggest turnround effort in airline’s history
      • Wine growers fear funding will wither after fall of Silicon Valley Bank
    • Tech
    • Markets
      Sections
      • Markets Home
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
      Most Read
      • Money market funds swell by more than $286bn as investors pull deposits from banks
      • Live news: US derivatives regulator sues Binance and founder Changpeng Zhao
      • Russia embraces China’s renminbi in face of western sanctions
      • Jay Powell and Janet Yellen struggle to calm nerves in banking crisis
      • Hedge funds scale back bets against Scottish Mortgage
    • Climate
    • Opinion
      Sections
      • Opinion Home
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
      Most Read
      • A new technology boom is at hand
      • Credit Suisse’s demise: a new twist on the ‘Swiss finish’
      • Why five days in the office don’t add up
      • The unstoppable rise of government rescues
      • Japan remains free from the tyranny of tipping
    • Work & Careers
      Sections
      • Work & Careers Home
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
      Most Read
      • Matthew Desmond: ‘America does so much more to subsidise affluence than alleviate poverty’
      • Culture clash: the challenge of uniting fierce rivals UBS and Credit Suisse
    • Life & Arts
      Sections
      • Life & Arts Home
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
      Most Read
      • Everything I, an Italian, thought I knew about Italian food is wrong
      • My life with Ozempic – a weight-loss diary
      • To Istanbul, by train
      • Is France on the road to a Sixth Republic?
      • Perfectly peaceful Puglian retreats
    • HTSI
    MenuSearch
    • Home
    • World
    • US
    • Companies
    • Tech
    • Markets
    • Climate
    • Opinion
    • Work & Careers
    • Life & Arts
    • HTSI
    Financial Times
    SubscribeSign In

    Covid-19 vaccines

    Add to myFT Digest

    Add this topic to your myFT Digest for news straight to your inbox

    • Monday, 27 March, 2023
      BioNTech
      BioNTech forecasts slump in sales as demand for Covid jab wanes

      Expected fall highlights challenges for pharmaceutical companies that experienced pandemic windfall

    • Wednesday, 15 March, 2023
      Taiwan
      Taiwan loses diplomatic ally as Honduras confirms link to China

      Central American nation was one of Taipei’s last partners in Washington’s backyard

    • Tuesday, 14 March, 2023
      Pfizer’s revised EU Covid vaccine contract meets resistance

      Four member states including Poland say amended deal is not ‘fair solution’ to surplus of shots

    • Tuesday, 7 March, 2023
      UK spring Covid boosters will target elderly and vulnerable

      Health secretary confirms acceptance of advice from expert committee to ‘bridge the gap’ to autumn

    • Wednesday, 15 February, 2023
      CanSino says vaccine demand down after China’s mass Covid infections

      Pharma group hopes for approval of mRNA vaccine for booster shots

    • Sunday, 29 January, 2023
      Drugs research
      RQ Bio partners with AstraZeneca in Covid antibody fight

      UK biotech racing to keep antibody up to date with latest variants

    • Tuesday, 10 January, 2023
      Chinese bank tries to entice wealthy customers with mRNA vaccines

      Hong Kong-based lender seeks to cater to mainlanders’ demand for western jabs

    • Monday, 9 January, 2023
      CureVac GmbH
      Covid vaccine makers CureVac and Novavax appoint new chiefs

      Pharmaceutical groups to part ways with longstanding executives

    • Monday, 9 January, 2023
      InterviewPharmaceuticals sector
      SK Bioscience says ‘national pride’ prevents China from accepting foreign Covid jabs

      South Korean vaccine maker looks elsewhere to expand overseas business

    • Friday, 6 January, 2023
      New Chinese mRNA Covid vaccine shows positive early results

      Jab developed by CanSinoBio could help nation grappling with a wave of infection

    • Thursday, 5 January, 2023
      ExplainerCoronavirus pandemic
      How serious is the threat of new Covid-19 variants?

      A surge in cases after China lifted restrictions has sparked concerns that a dangerous new strain could emerge

    • Tuesday, 3 January, 2023
      EU offers free Covid-19 vaccines to China to help curb outbreak

      Beijing rejects Brussels’ offer, citing full control of situation

    • Monday, 26 December, 2022
      Chinese society
      Chinese vaccine tourists flock to Macau for mRNA Covid jabs

      Explosion of cases and ban on more effective western shots lead residents to look abroad

    • Monday, 12 December, 2022
      China warned to accelerate approval of updated jabs to tackle Covid ‘tsunami’

      Authorities have relied on vaccines made using original strain found in Wuhan

    • Wednesday, 7 December, 2022
      Coronavirus pandemic
      China risks ‘wave of infections’ after relaxing zero-Covid policy, warns Fauci

      Joe Biden’s chief medical adviser urges Beijing to approve use of western vaccines

    • Tuesday, 6 December, 2022
      News in-depthChinese politics & policy
      China’s elderly vaccine refuseniks pose obstacle for Xi Jinping

      Nearly 90mn Chinese are insufficiently protected against Covid as Beijing begins to unwind pandemic controls

    • Monday, 5 December, 2022
      FIFA World Cup
      World Cup briefing: Final whistle blows for Qatar’s shortlived stadiums

      Plus, Japan look to make history, defensive Dutch plot different course

    • Thursday, 1 December, 2022
      US warns Beijing it cannot control Covid-19 without western jabs

      Joe Biden’s coronavirus tsar says Chinese vaccines are ‘not as good’ as alternatives

    • Tuesday, 29 November, 2022
      Medical science
      Epidemic coalition sets out plan to develop future vaccines in 100 days

      Cepi releases blueprint to move three times faster against a new virus than during Covid-19 pandemic

    • Friday, 25 November, 2022
      News in-depthChinese politics & policy
      ‘No way we can open’: China’s zero-Covid exit plans unravel

      Economic and social costs are climbing but Beijing has failed to offer a way out of endless lockdowns

    • Thursday, 10 November, 2022
      AstraZeneca PLC
      AstraZeneca drops submission to US regulators for Covid-19 vaccine approval

      Plan abandoned almost two years after initial approval in UK and Europe

    • Tuesday, 8 November, 2022
      Patent wars: Moderna’s battle for the spoils of Covid vaccines

      Ending of pharma group’s IP truce spells fight for future of mRNA technology

    • Monday, 7 November, 2022
      BioNTech
      Profits drop at BioNTech as Covid vaccine demand wanes

      Fall from €3.2bn in the third quarter of 2021 to €1.8bn

    • Thursday, 3 November, 2022
      Moderna
      Moderna cuts Covid vaccine sales forecast

      Jab maker ties weaker revenue outlook to delivery delays and manufacturing issues

    • Wednesday, 2 November, 2022
      Chinese equities
      Chinese stocks boosted by planned rollout of CanSino’s inhalable Covid vaccine

      Market rallies on hopes of looser coronavirus lockdown measures and travel restrictions

    Previous page You are on page 1 Next page

    Recommended

    Covid-19 vaccine tracker: Lowest-income countries lag further behind rest of the world
    Covid vaccine development: The shots available and the doses administered
    In graphics: the UK vaccine supply chain
    Coronavirus: free to read
    Coronavirus tracker: the latest figures as countries fight the Covid-19 resurgence

    Be part of FT Community

    Discover unmissable flagship events and members only communities to expand your thinking and elevate your career

    FT Live
    Global Pharma and Biotech Summit
    Driving Investment and Innovation in Life Sciences
    Tuesday, 7th NovemberUK & Online
    Learn more about FT Community

    Useful links

    Support

    View Site TipsHelp CentreContact UsAbout UsAccessibilitymyFT TourCareers

    Legal & Privacy

    Terms & ConditionsPrivacy PolicyCookiesCopyrightSlavery Statement & Policies

    Services

    Share News Tips SecurelyIndividual SubscriptionsGroup SubscriptionsRepublishingExecutive Job SearchAdvertise with the FTFollow the FT on TwitterFT ChannelsSecondary Schools

    Tools

    PortfolioToday's Newspaper (ePaper)Alerts HubBusiness School RankingsEnterprise ToolsNews feedNewslettersCurrency Converter

    Community & Events

    FT CommunityFT Live EventsFT ForumsFT Board DirectorBoard Director Programme

    More from the FT Group

    Markets data delayed by at least 15 minutes. © THE FINANCIAL TIMES LTD 2023. FT and ‘Financial Times’ are trademarks of The Financial Times Ltd.
    The Financial Times and its journalism are subject to a self-regulation regime under the FT Editorial Code of Practice.
    Financial Times

    International Edition

    Subscribe for full access
    • Switch to UK Edition

    Top sections

    • Home
    • World
      • Global Economy
      • UK
      • US
      • China
      • Africa
      • Asia Pacific
      • Emerging Markets
      • Europe
      • War in Ukraine
      • Americas
      • Middle East & North Africa
      • Australia & NZ
    • US
      • US Economy
      • US Companies
      • US Politics & Policy
    • Companies
      • Banks in turmoil
      • Energy
      • Financials
      • Health
      • Industrials
      • Media
      • Professional Services
      • Retail & Consumer
      • Tech Sector
      • Telecoms
      • Transport
    • Tech
    • Markets
      • Alphaville
      • Markets Data
      • Cryptofinance
      • Capital Markets
      • Commodities
      • Currencies
      • Equities
      • Fund Management
      • Trading
      • Moral Money
      • ETF Hub
    • Climate
    • Opinion
      • Columnists
      • The FT View
      • Lex
      • Obituaries
      • Letters
    • Work & Careers
      • Business School Rankings
      • Business Education
      • Entrepreneurship
      • Recruitment
      • Business Books
      • Business Travel
    • Life & Arts
      • Arts
      • Books
      • Food & Drink
      • FT Magazine
      • House & Home
      • Style
      • Travel
      • FT Globetrotter
    • Personal Finance
      • Property & Mortgages
      • Investments
      • Pensions
      • Tax
      • Banking & Savings
      • Advice & Comment
      • Next Act
    • HTSI
    • Special Reports

    FT recommends

    • Lex
    • Alphaville
    • Lunch with the FT
    • FT Globetrotter
    • #techAsia
    • Moral Money
    • FTfm
    • Newsletters
    • Video
    • Podcasts
    • News feed
    • FT Live Events
    • FT Forums
    • Board Director Programme
    • myFT
    • Portfolio
    • Today's Newspaper (ePaper)
    • Crossword
    • Our Apps
    • Help Centre
    • Subscribe
    • Sign In